Trending NewsTrending NewsNASDAQ:SPRY ARS Pharmaceuticals (SPRY) Stock Price, News & Analysis $6.37 +0.13 (+2.08%) As of 11:01 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About ARS Pharmaceuticals Stock (NASDAQ:SPRY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ARS Pharmaceuticals alerts:Sign Up Key Stats Today's Range$6.12▼$6.5050-Day Range$5.13▼$10.5452-Week Range$4.91▼$15.09Volume509,883 shsAverage Volume1.75 million shsMarket Capitalization$632.54 millionP/E RatioN/ADividend YieldN/APrice Target$28.20Consensus RatingModerate Buy Company Overview ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California. Read More ARS Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks69th Percentile Overall ScoreSPRY MarketRank™: ARS Pharmaceuticals scored higher than 69% of companies evaluated by MarketBeat, and ranked 282nd out of 911 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingARS Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialARS Pharmaceuticals has a consensus price target of $28.20, representing about 351.9% upside from its current price of $6.24.Amount of Analyst CoverageARS Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about ARS Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for ARS Pharmaceuticals are expected to grow in the coming year, from ($1.95) to ($1.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ARS Pharmaceuticals is -2.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ARS Pharmaceuticals is -2.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioARS Pharmaceuticals has a P/B Ratio of 5.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted32.63% of the float of ARS Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverARS Pharmaceuticals has a short interest ratio ("days to cover") of 7.78.Change versus previous monthShort interest in ARS Pharmaceuticals has recently decreased by 5.37%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldARS Pharmaceuticals does not currently pay a dividend.Dividend GrowthARS Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment0.01 News SentimentARS Pharmaceuticals has a news sentiment score of 0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 32 news articles for ARS Pharmaceuticals this week, compared to 5 articles on an average week.Search Interest7 people have searched for SPRY on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.MarketBeat Follows4 people have added ARS Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, ARS Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $283,550.00 in company stock.Percentage Held by Insiders33.80% of the stock of ARS Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions68.16% of the stock of ARS Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ARS Pharmaceuticals' insider trading history. Receive SPRY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ARS Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SPRY Stock News HeadlinesSPRY Shareholder Alert: ARS Pharmaceuticals, Inc. Securities Class Action Lawsuit - Investors Should Contact The Gross Law Firm34 minutes ago | prnewswire.comSPRY Shareholder Alert: October 5, 2026 Lead Plaintiff Deadline in ARS Pharmaceuticals Inc. Securities Class Action - Contact SueWallSt40 minutes ago | globenewswire.comSomeone just dumped the biggest gold fund.Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing total outflows to 14 billion. At the same time, the World Gold Council recorded the highest quarterly central bank gold buying on record, with buyers taking physical delivery instead of paper shares.August 18 at 1:00 AM | Behind the Markets (Ad)ARS Pharma: New CEO's Program Of Reducing Costs While Increasing Revenues Makes A Buy1 hour ago | seekingalpha.comRobbins LLP Urges SPRY Stockholders Who Lost Money Investing in ARS Pharmaceuticals Inc. to Contact the Firm for Information About Leading the Class Action LawsuitAugust 17 at 7:11 PM | prnewswire.comBragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against ARS Pharmaceuticals and Encourages Investors to Contact the FirmAugust 17 at 6:00 PM | globenewswire.comBronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor HarmAugust 17 at 12:00 PM | globenewswire.comSPRY Investor Alert: ARS Pharmaceuticals Inc. Securities Class Action Notice - Contact Levi & KorsinskyAugust 17 at 11:24 AM | globenewswire.comSee More Headlines SPRY Stock Analysis - Frequently Asked Questions How have SPRY shares performed this year? ARS Pharmaceuticals' stock was trading at $11.65 at the beginning of 2026. Since then, SPRY stock has decreased by 46.4% and is now trading at $6.24. How were ARS Pharmaceuticals' earnings last quarter? ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) announced its earnings results on Thursday, August, 13th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by $0.15. The firm had revenue of $33.66 million for the quarter, compared to the consensus estimate of $31.32 million. ARS Pharmaceuticals had a negative trailing twelve-month return on equity of 256.67% and a negative net margin of 184.24%. Read the conference call transcript. When did ARS Pharmaceuticals IPO? ARS Pharmaceuticals (SPRY) raised $207 million in an initial public offering on Friday, December 4th 2020. The company issued 11,500,000 shares at a price of $17.00-$19.00 per share. Who are ARS Pharmaceuticals' major shareholders? ARS Pharmaceuticals' top institutional shareholders include BlackRock Inc. (5.35%), Tejara Capital Ltd (0.61%), ADAR1 Capital Management LLC (0.61%) and Bank of America Corp DE (0.47%). Insiders that own company stock include Ra Capital Management, LP, Sarina Tanimoto, Richard E Lowenthal, Laura Shawver, Alexander A Fitzpatrick, Eric Karas, Brian Dorsey, Kathleen D Scott, Peter A Thompson, Justin Chakma and Brent L Saunders. View institutional ownership trends. How do I buy shares of ARS Pharmaceuticals? Shares of SPRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ARS Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that ARS Pharmaceuticals investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), Voyager Therapeutics (VYGR), AUO (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings8/13/2026Today8/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4w+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 For the last 4 weeks, SPRY's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:SPRY CIK1671858 Webars-pharma.com Phone206-456-2900FaxN/AEmployees90Year Founded2015Price Target and Rating Average Price Target for ARS Pharmaceuticals$28.20 High Price Target$32.00 Low Price Target$24.00 Potential Upside/Downside+339.4%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($2.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$171.30 million Net Margins-184.24% Pretax Margin-184.31% Return on Equity-256.67% Return on Assets-69.63% Debt Debt-to-Equity Ratio13.72 Current Ratio3.48 Quick Ratio3.28 Sales & Book Value Annual Sales$84.28 million Price / Sales7.56 Cash FlowN/A Price / Cash FlowN/A Book Value$1.16 per share Price / Book5.53Miscellaneous Outstanding Shares99,300,000Free Float65,739,000Market Cap$637.31 million OptionableOptionable Beta0.98 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:SPRY) was last updated on 8/18/2026 by MarketBeat.com Staff. From Our PartnersThree oil giants buried the same discovery for 50 yearsIn 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...Behind the Markets | SponsoredRiot Platforms’ $9.1 billion move with AnthropicRiot Platforms signed a 20-year, 9.1 billion dollar agreement with Anthropic for 191 megawatts of data-center ...The Oxford Club | SponsoredElon's Terrifying Warning: America Is "1,000% Going Bankrupt"The national debt just crossed $39 trillion, and Elon Musk - former head of the Department of Government Effic...American Hartford Gold | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSMX Could Turn Proof Technology into Major Profit!SMX (Security Matters) PLC embeds invisible molecular markers into materials like plastics, metals, fuels, and...Smallcaps Daily | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredAmerican retirees will miss THIS. Big Banks just moved in.Central banks spent nearly $130 billion on physical gold last year, on top of $145 billion the year before. Q1...Cedar Gold Group | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ARS Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
